ReviewCurrent pharmaceutical design2017
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis.
Review in Current pharmaceutical design, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Coronary Stent Thrombosis in COVID-19 Patients: A Systematic Review of Cases Reported Worldwide.Viruses · 2022Pooled it
- Expression of Inflammatory Markers in Ascending Thoracic Aorta in Patients with Obstructive Sleep Apnea.International journal of molecular sciences · 2026Article
- Inflammation-induced impairment of synaptic plasticity accelerates atherosclerosis co-depression disease: insights from bioinformatics analysis and transcriptomics.Cell & bioscience · 2026Article
- A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part I.Life (Basel, Switzerland) · 2025Review
- Hotspots and scientometrics in gallbladder cancer surgery research: a bibliometric and visualization analysis (2014-2024).Frontiers in oncology · 2025Article
- Dietary ellagic acid blocks inflammation-associated atherosclerotic plaque formation in cholesterol-fed apoE-deficient mice.Nutrition research and practice · 2024Article
- Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2.Chinese journal of integrative medicine · 2024Review
- Analysis of the Model of Atherosclerosis Formation in Pig Hearts as a Result of Impaired Activity of DNA Repair Enzymes.International journal of molecular sciences · 2024Article
- Reversal of atherosclerosis by restoration of vascular copper homeostasis.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Impact of theFrontiers in cardiovascular medicine · 2024Review
- SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Review
- Activation of the High Mobility Group Box 1/Receptor for Advanced Glycation Endproducts /NOD-like Receptor Family Pyrin Domain-Containing 3 Axis Under Chronic Intermittent Hypoxia Induction Promotes the Progression of Atherosclerosis in ApoEJournal of the American Heart Association · 2023Article
- NEDD4 attenuates oxidized low‑density lipoprotein‑induced inflammation and dysfunction in vascular endothelial cells via regulating APEX1 expression.Experimental and therapeutic medicine · 2023Article
- Natural Monoterpenes as Potential Therapeutic Agents against Atherosclerosis.International journal of molecular sciences · 2023Review
- Anti-malarial artesunate ameliorates atherosclerosis by modulating arterial inflammatory responsesFrontiers in pharmacology · 2023Article
- Article
- Serum IL-38 Level Was Associated with Incidence of MACE in the STEMI Patients.International journal of general medicine · 2023Article
- Pathomechanisms of SARS-CoV-2 infection and development of atherosclerosis in patients with COVID-19: A review.Medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully. Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory strategy in atherosclerotic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.